Testimony Before the FDA’s Arthritis Advisory Committee Regarding Lesinurad
View PDF: Summary | Presentation
Public Citizen opposes Food and Drug Administration (FDA) approval of the new drug application for lesinurad for treatment of hyperuricemia associated with gout because the drug offers meager clinically meaningful benefits relative to placebo for gout patients with hyperuricemia and has serious risks, including definite significant renal toxicity and possible cardiovascular toxicity. As a result, the drug would cause much more harm than benefit.